We are live on ! Find out more
ASMB icon

Assembly Biosciences
ASMB

Fund managers haven’t disclosed any holdings of ASMB yet.

ASMB Hedge Fund Activity: Q1 2026 in Review

75 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q1 2026, worth a combined $376M — down 19% from $467M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new ASMB positions and 10 closed out — a net gain of 7 holders — while 28 added to existing stakes and 17 trimmed.

The largest buyer was Parkman Healthcare Partners, adding an estimated $4.62M. The largest seller was Point72 Asset Management, cutting an estimated $7.32M.

  • 75 institutional investors held Assembly Biosciences (ASMB) as of Q1 2026, up from 69 in Q4 2025.
  • Funds reported $376M of Assembly Biosciences stock for Q1 2026, down 19% quarter-over-quarter.
  • 17 funds opened new Assembly Biosciences positions in Q1 2026 and 10 closed out, a net change of +7 holders.
  • The largest Assembly Biosciences buyer in Q1 2026 was Parkman Healthcare Partners, an estimated $4.62M added.
  • The largest Assembly Biosciences seller in Q1 2026 was Point72 Asset Management, an estimated $7.32M sold.

Based on aggregated 13F filings for Q1 2026.